Therapeutics of osteoarthritis and pharmacological mechanisms: A focus on RANK/RANKL signaling

Biomed Pharmacother. 2023 Nov:167:115646. doi: 10.1016/j.biopha.2023.115646. Epub 2023 Oct 5.

Abstract

Osteoarthritis (OA) is a chronic degenerative disease afflicting millions globally. Despite the development of numerous pharmacological treatments for OA, a substantial unmet need for effective therapies persists. The RANK/RANKL signaling pathway has emerged as a promising therapeutic target for OA, owing to its pivotal role in regulating osteoclast differentiation and activity. In this comprehensive review, we aim to elucidate the relevant mechanisms of OA mediated by RANK/RANKL signaling, including bone remodeling, inflammation, cartilage degradation, osteophyte formation, and pain sensitization. Furthermore, we discuss and summarize the cutting-edge strategies targeting RANK/RANKL signaling for OA therapy, encompassing approaches such as gene-based interventions and biomaterials-aided pharmacotherapy. In addition, we highlight the prevailing challenges associated with pharmacological OA treatments and explore potential future directions, approached through a clinical-translational lens.

Keywords: Osteoarthritis; Pharmacological therapy; RANK; RANKL; Signaling.

Publication types

  • Review

MeSH terms

  • Bone Remodeling
  • Cartilage, Articular* / metabolism
  • Humans
  • Inflammation / metabolism
  • Osteoarthritis* / drug therapy
  • Osteoarthritis* / metabolism
  • Osteoprotegerin / metabolism
  • RANK Ligand / metabolism
  • Signal Transduction

Substances

  • Osteoprotegerin
  • RANK Ligand